PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

Abstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish regist...

Full description

Bibliographic Details
Main Authors: Deirdre Cronin-Fenton, Tapashi Dalvi, Naimisha Movva, Lars Pedersen, Hanh Hansen, Jon Fryzek, Elizabeth Hedgeman, Anders Mellemgaard, Torben R. Rasmussen, Norah Shire, Stephen Hamilton-Dutoit, Mette Nørgaard
Format: Article
Language:English
Published: Nature Portfolio 2021-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-96486-2

Internet

https://doi.org/10.1038/s41598-021-96486-2

Similar Items